Could Anika Therapeutics Inc (NASDAQ:ANIK) See a Reversal After Less Sellers Came In?

September 15, 2018 - By Megan Stone

Anika Therapeutics, Inc. (NASDAQ:ANIK) Logo

Investors sentiment increased to 1.32 in 2018 Q2. Its up 0.08, from 1.24 in 2018Q1. It improved, as 16 investors sold Anika Therapeutics, Inc. shares while 43 reduced holdings. 29 funds opened positions while 49 raised stakes. 13.16 million shares or 7.40% more from 12.25 million shares in 2018Q1 were reported.
Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK). 88 were accumulated by Advisory Service Network Llc. Engineers Gate Manager Ltd Partnership accumulated 23,972 shares. Regions Financial reported 491 shares. Portolan Cap Management Ltd Liability Company reported 162,080 shares stake. Smith Asset Mngmt Gp L P has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Legal General Grp Plc, United Kingdom-based fund reported 29,039 shares. Bbva Compass National Bank Incorporated has invested 0.03% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Price T Rowe Assocs Md stated it has 0% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK). The Massachusetts-based State Street has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Prelude Limited Liability Company reported 3,207 shares. First Tru Advsr L P invested in 0% or 7,804 shares. Bank Of Ny Mellon owns 502,703 shares for 0% of their portfolio. Moreover, Stone Ridge Asset Limited Liability Company has 0.01% invested in Anika Therapeutics, Inc. (NASDAQ:ANIK). Piermont Cap Mngmt Incorporated has 45,124 shares.

The stock of Anika Therapeutics Inc (NASDAQ:ANIK) registered a decrease of 1.26% in short interest. ANIK’s total short interest was 2.51M shares in September as published by FINRA. Its down 1.26% from 2.54 million shares, reported previously. With 82,200 shares average volume, it will take short sellers 31 days to cover their ANIK’s short positions. The short interest to Anika Therapeutics Inc’s float is 17.64%.

The stock decreased 1.11% or $0.46 during the last trading session, reaching $40.94. About 104,811 shares traded. Anika Therapeutics, Inc. (NASDAQ:ANIK) has declined 25.99% since September 15, 2017 and is downtrending. It has underperformed by 41.61% the S&P500.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company has market cap of $597.05 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology. It has a 33.53 P/E ratio. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

Among 2 analysts covering Anika Therapeutics (NASDAQ:ANIK), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Anika Therapeutics had 3 analyst reports since May 4, 2018 according to SRatingsIntel. The stock of Anika Therapeutics, Inc. (NASDAQ:ANIK) earned “Outperform” rating by Barrington Research on Friday, July 27. First Analysis downgraded Anika Therapeutics, Inc. (NASDAQ:ANIK) rating on Wednesday, June 20. First Analysis has “Hold” rating and $3400 target. The firm earned “Outperform” rating on Friday, May 4 by Barrington Research.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.